LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2.

Publication Type
Journal Article
Year of Publication
2018
Authors
Heeren, Tjebo F C; Kitka, Diána; Florea, Daniela; Clemons, Traci E; Chew, Emily Y; Bird, Alan C; Pauleikhoff, Daniel; Charbel Issa, Peter; Holz, Frank G; Peto, Tunde
Secondary
Retina
Volume
38 Suppl 1
Pagination
S20-S26
Date Published
2018 01
Keywords
Disease Progression; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Imaging, Three-Dimensional; Macula Lutea; Photic Stimulation; Prospective Studies; Retinal Vessels; Scotoma; Telangiectasia, Hereditary Hemorrhagic; Time Factors; Tomography, Optical Coherence; visual acuity; Visual Field Tests; Visual Fields
Abstract

PURPOSE: To compare ellipsoid zone (EZ) loss and functional loss in macular telangiectasia (MacTel) type 2 longitudinally.

METHODS: Prospective natural history study. Ellipsoid zone loss was measured in en-face images created from spectral domain optical coherence tomography. Functional loss was assessed by best-corrected visual acuity and microperimetry, counting the number of test points with impaired function.

RESULTS: A total of 56 eyes of 31 participants were followed for 4.5 ± 1.2 years. Ellipsoid zone loss was 18,600 ± 3,917.3 pixel at baseline (≈0.59 mm) and increased 2,627.8 ± 427.9 pixel (≈0.08 mm) per year. Best-corrected visual acuity decreased 2.2 ± 0.9 letters per year. Change in EZ loss correlated significantly with change in relative and absolute scotomas (r = 0.62; P-value < 0.0001 and r = 0.72; P-value < 0.0001), but not with loss of best-corrected visual acuity. Functional loss showed a similar frequency of progression as EZ loss, but a higher rate of "regression," likely due to higher variability of the measurement, assuming a progressive neurodegenerative disease.

CONCLUSION: The results of the authors support EZ loss as surrogate measure for visual function in MacTel type 2. Being objective, EZ loss might be considered more suitable than microperimetry as primary end point in future interventional trials.